Table 2.
This study summarizes the exposure to Hg from Thimerosal-preserved HepB immunizations administered among male cases with a premature puberty diagnosis compared to the male control subjects 1, within the database of the VSD.
| Group Examined | Number of Male Cases Diagnosed with Premature Puberty (%) | Number of Male Controls without a Premature Puberty Diagnosis (%) | Odds Ratio (95% CI) | p-Value |
|---|---|---|---|---|
| Group IV | ||||
| 12.5 µg Hg within 1st month | 10 (35.71) | 10,584 (37.81) | ||
| 0.914 (0.422–1.98) | >0.99 | |||
| 0 µg Hg within 1st month | 18 (64.29) | 17,405 (62.19) | ||
| Group V | ||||
| 25 µg Hg within first 2 months | 9 (33.33) | 10,594 (38.40) | ||
| 0.802 (0.360–1.786) | >0.65 | |||
| 0 µg Hg within first 2 months | 18 (66.67) | 16,991 (61.60) | ||
| Group VI | ||||
| 37.5 µg Hg within first 6 months | 3 (75.00) | 1979 (67.06) | ||
| 1.474 (0.153–14.184) | >0.99 | |||
| 0 µg Hg within first 6 months | 1 (25.00) | 972 (32.94) |
1 The control subjects were enrolled continuously from their birth, for a minimum of 5.59 years (the mean age of their initial premature puberty diagnosis plus the SD of mean age of their initial premature puberty diagnosis). Hg = mercury, µg = microgram, SD = standard deviation.